Stereotaxis Inc.
STXS Healthcare Medical Instruments & Supplies
Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 12.8%, EPS was flat and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow STXS
Stereotaxis Inc. (STXS) Piotroski F-score
Stereotaxis Inc.'s Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | 2.00 |
| FY2024 | 3 | 0.00 |
| FY2023 | 3 | 1.00 |
| FY2022 | 2 | (1.00) |
| FY2021 | 3 | (1.00) |
| FY2020 | 4 | 2.00 |
| FY2019 | 2 | (3.00) |
| FY2018 | 5 | 1.00 |
| FY2017 | 4 | 1.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (46.30%) | (57.21%) | Fail | 0 |
| Positive operating cash flow | (13.68m) | (8.50m) | Fail | 0 |
| Rising return on assets | (46.30%) | (57.21%) | Pass | 1 |
| Cash flow above net income | 9.23m | 16.86m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 1.51 | 1.22 | Pass | 1 |
| No new shares issued | 90,957,300 | 85,183,300 | Fail | 0 |
| Rising gross margin | 52.73% | 54.22% | Fail | 0 |
| Rising asset turnover | 0.65 | 0.61 | Pass | 1 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| UTMD Utah Medical Products, Inc. compare | 6 |
| PDEX Pro-Dex, Inc. compare | 6 |
| POCI Precision Optics Corp. compare | 5 |
| KRMD KORU Medical Systems, Inc. compare | 5 |
| STXS Stereotaxis Inc. | 5 |
| NYXH Nyxoah SA compare | 3 |
| ZTEKF Zentek Ltd. compare | 1 |
| DXR Daxor Corporation compare | — |
| MBOT Microbot Medical Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover